A5100614685- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Advanced Biosensing Techniques and Applications
- HER2/EGFR in Cancer Research
- Nonmelanoma Skin Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cutaneous lymphoproliferative disorders research
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Economic and Financial Impacts of Cancer
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Urinary and Genital Oncology Studies
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
Peking University
2016-2025
Peking University Cancer Hospital
2016-2025
Hebei Medical University
2025
Xingtai People's Hospital
2025
Chinese PLA General Hospital
2024
University of Pennsylvania
2013-2024
Xiyuan Hospital
2024
Gansu Provincial Hospital
2024
National Institute of Diabetes and Digestive and Kidney Diseases
2023
ProQuest (United States)
2023
Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients metastatic renal-cell carcinoma. This 3, randomized trial the efficacy safety of pazopanib first-line therapy. We randomly assigned 1110 clear-cell, carcinoma, 1:1 ratio, to receive continuous dose (800 mg once daily; 557 patients) 6-week cycles (50 daily for 4 weeks, followed by 2 weeks without treatment; 553 patients). The primary end...
Malignant melanoma is a rare disease in Asia, and knowledge on its characteristics clinical outcome Asian patients limited. The purpose of this observational study was to determine the presentation with China.A database prospectively established for analysis. elements included basic demographic data prognosticators previously reported literature, as well follow-up including after treatment. Medical record all pathologically diagnosed malignant consulted our center since 2006 were retrieved...
Abstract Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity comprehensive mutation data on this rare tumor type. To better understand genomic landscape melanoma, here we describe whole genome sequencing analysis 67 tumors validation driver gene mutations by exome 45 tumors. Tumors have a low point burden high numbers structural variants, including recurrent rearrangements targeting TERT, CDK4 MDM2 . Significantly mutated genes are NRAS , BRAF...
KIT aberrations were described in acral and mucosal melanomas largely Caucasian populations. Asian populations are more prone to develop than cutaneous melanomas, may harbor a high frequency of aberrations.Melanoma subtypes (n = 502) analyzed histologically determine melanoma subtype. Tissue samples for mutations exons 9, 11, 13, 17, 18 gene genomic DNA by PCR amplification Sanger sequencing. The copy numbers the quantitative PCR, protein expression levels (CD117) determined...
Abstract Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients HER2+ locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. Patients Methods: This was phase II, open-label, multicenter, single-arm study (IHC status 3+ 2+) mUC who previously failed at least one line systemic chemotherapy. The primary endpoint objective response rate (ORR) assessed by blinded...
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory either therapy alone.We conducted a single-center, phase IB trial evaluating safety preliminary efficacy toripalimab, humanized immunoglobulin G4 monoclonal...
Abstract Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation patient survival outcomes during anti–PD-1 monotherapy remains unclear. Experimental Design: In this multicenter retrospective analysis, patients treated between 2009 2019 detailed use, data were identified from five independent...
To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard regular therapies.
Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal has not been established. We conducted a randomized phase II clinical trial in patients resected to compare the efficacy safety of high-dose IFN-α2b (HDI) temozolomide-based chemotherapy as therapy.Patients stage II/III after surgery were into three groups: observation group (group A, alone), HDI B, treated 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 U IFN-α2b), temozolomide...
Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T therapy treatment other solid tumors has been limited. We incorporated 4-1BB into anti-GD2 to test their cytotoxicity melanoma vitro and vivo. Moreover, we reported expression ganglioside GD2 non-Caucasian populations for first time, thus providing a basis future research. This study included tumor samples from 288 at Peking...
The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib patients with KIT-mutated advanced melanoma without prior KIT treatment.Forty-two were enrolled and treated 400 mg twice daily. TEAM originally included a comparator arm of dacarbazine (DTIC)-treated patients; design was amended to single-arm due an observed low number melanomas. Thirteen randomized DTIC before protocol amendment removing this study arm....
JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate safety, tolerability, clinical activity JS001 advanced melanoma or urologic cancer patients who are refractory standard systemic therapy. In dose escalation cohorts, subjects initially received single-dose, intravenous infusion were followed for 28 days by...
Background Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) that was engineered to minimize FcγR on macrophages in order abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance potential resistance anti-PD-1 therapy. Methods The purpose this phase 1/2, open-label, non-comparative study examine the safety, tolerability, antitumor activity tislelizumab adult (≥18 years)...
Pembrolizumab shows robust antitumor activity and favorable safety in metastatic melanoma. KEYNOTE-151 evaluated pembrolizumab Chinese patients, who have more aggressive melanoma subtypes than other populations. patients aged ≥18 years with advanced previously treated one line of therapy received 2 mg/kg every 3 weeks for 35 cycles or until confirmed disease progression, intolerable toxicity, study withdrawal. Primary end points were objective response rate (ORR) per RECIST v1.1 by blinded...
Purpose: Effective therapies for the majority of metastatic acral melanoma patients have not been established. Thus, we investigated genetic aberrations CDK4 pathway in and evaluated efficacy CDK4/6 inhibitors targeted therapy melanoma.Experimental Design: A total 514 primary samples were examined copy number variations (CNV) pathway-related genes, including Cdk4, Ccnd1, P16INK4a , by QuantiGenePlex DNA Assay. The sensitivity established cell lines patient-derived xenograft (PDX) containing...
PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of melanoma benefit from this approach. The mechanism triggering the innate resistance anti-PD-1 therapy remains unclear.Experimental Design: Whole-exome sequencing (WES) RNA (RNA-Seq) analyses were performed training cohort (n = 31) using baseline tumor biopsies treated antibody. Copy-number variations (CNVs) for genes CDK4, CCND1, CDKN2A assayed TaqMan...
Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients the treatment most likely be of benefit. Existing gene expression profiling (GEP)-based primarily focused on measuring a T cell-inflamed tumor microenvironment that contributes positively response ICI. Here, we identified an immunosuppression signature (IMS) through analyzing RNA sequencing data...
Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations remain poorly characterized other ethnic groups, such as East Asian, Hispanic African.To determine the of PD-1 different groups.Clinical data patients with unresectable or melanoma treated anti-PD-1 between 2009 2019 were collected retrospectively from five independent institutions USA, Australia China. Tumour response,...
Mucosal melanoma is an aggressive subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination toripalimab, a humanized IgG4 mAb against PD-1, showed promising rate patients metastatic mucosal (MM) phase Ib study. Here, we report the updated overall survival (OS), duration of (DoR), and biomarker analysis results.Patients advanced MM received toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined axitinib 5 mg orally two times per day until...